2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B0098A
    Doxazosin mesylate 77883-43-3 98.49%
    Doxazosin mesylate (UK 33274 mesylate) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.
    Doxazosin mesylate
  • HY-101952G
    Prostaglandin E2 (GMP) 363-24-6 98%
    Prostaglandin E2 (GMP) is Prostaglandin E2 (HY-101952) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Prostaglandin E2, an inflammatory mediator, is a endogenous hormone-like substance that participate in a wide range of body functions.
    Prostaglandin E2 (GMP)
  • HY-12593
    GS967 1262618-39-2 99.55%
    GS967 (GS-458967) is a potent, and selective inhibitor of cardiac late sodium current (late INa ) with IC50 values of 0.13 and 0.21 μM for ventricular myocytes and isolated hearts, respectively.
    GS967
  • HY-15125
    (R)-(+)-Bay-K-8644 98791-67-4 99.36%
    (R)-(+)-Bay-K-8644 is a calcium channel inhibitor. (R)-(+)-Bay-K-8644 inhibits Ba2+ currents (IBa) (IC50=975 nM).
    (R)-(+)-Bay-K-8644
  • HY-19328
    ACY-775 1375466-18-4 99.71%
    ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (HDAC6) with an IC50 of 7.5 nM. ACY775 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2).
    ACY-775
  • HY-B0079
    Sugammadex sodium 343306-79-6 98.0%
    Sugammadex sodium is a synthetic γ-cyclodextrin derivative, and acts as a reversal agent for neuromuscular block. Sugammadex sodium shows nephroprotective effect in ischemia-reperfusion injury.
    Sugammadex sodium
  • HY-B0259
    Indapamide 26807-65-8 99.62%
    Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy.
    Indapamide
  • HY-B1438
    Canrenone 976-71-6 99.56%
    Canrenone (Aldadiene) is an aldosterone antagonist extensively used as a diuretic agent.
    Canrenone
  • HY-B1832
    Prednisone acetate 125-10-0 99.92%
    Prednisone acetate (Prednisone 21-acetate), a glucocorticoid, is an orally active Notch inhibitor. Prednisone acetate has anti-inflammatory activity and can enhance the immune response.
    Prednisone acetate
  • HY-N3460
    Isorhoifolin 552-57-8 99.96%
    Isorhoifolin is a flavonoid glycoside from Hemistepta lyrata. Isorhoifolin displays an anti-leakage effect.
    Isorhoifolin
  • HY-P0190
    Iberiotoxin 129203-60-7 ≥98.0%
    Iberiotoxin is a toxin isolated from Buthus tamulus scorpion venom. Iberiotoxin is a selective high conductance high conductance Ca2+-activated K+ channel inhibitor with a Kd of ~1 nM. Iberiotoxin does not block other types of voltage-dependent ion channels.
    Iberiotoxin
  • HY-100671
    L002 321695-57-2 99.44%
    L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an IC50 of 1.98 μM. L002 binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain, blocks histone acetylation and p53 acetylation, and inhibits STAT3 activation. L002 has the potential for hypertension-induced cardiac hypertrophy and fibrogenesis treatment.
    L002
  • HY-114758
    Pyridoxal isonicotinoyl hydrazone 737-86-0 99.96%
    Pyridoxal isonicotinoyl hydrazone is an orally active and lipophilic iron-specific chelator that acts as a non-competitive inhibitor of ferrochelatase (FECH) by binding iron ions. Pyridoxal isonicotinoyl hydrazone disrupts heme biosynthesis, leading to reduced FECH stability and increased protoporphyrin IX (PPIX) accumulation. Pyridoxal isonicotinoyl hydrazone is promising for research of iron-overload diseases (e.g., β-thalassemia).
    Pyridoxal isonicotinoyl hydrazone
  • HY-150123
    Quinidine methiodide 42982-87-6
    Quinidine methiodide is a metabolite of Quinidine. Quinidine is an antiarrhythmic agent.
    Quinidine methiodide
  • HY-156863
    GRK2 Inhibitor 2 2592436-21-8 99.92%
    GRK2 Inhibitor 2 is an orally active and selective G protein-coupled receptor kinase 2 (GRK) inhibitor with an IC50 of 19 nM. GRK2 Inhibitor 2 also inhibits Aurora-A with an IC50 of 137 nM. GRK2 Inhibitor 2 can be used in the study of congestive heart failure (HF).
    GRK2 Inhibitor 2
  • HY-A0084A
    Procainamide 51-06-9
    Procainamide (Procaine amide) is a specific and potent inhibitor of DNA methyltransferase 1 (DNMT1), which reactivates the expression of tumor suppressor factors by demethylating tumor suppressor genes. Procainamide induces vacuolization in various cell types and reduces cell proliferation and migration. Procainamide relaxes airway smooth muscle by activating potassium channels. Procainamide can be used in cancer and arrhythmia research.
    Procainamide
  • HY-P0205B
    Saralasin TFA 99.18%
    Saralasin ([Sar1,Ala8] Angiotensin II) TFA is an octapeptide analog of angiotensin II. Saralasin TFA is a competitive angiotensin II receptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin TFA can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension.
    Saralasin TFA
  • HY-N0470S3
    L-Lysine-13C6,15N2 hydrochloride 1200447-00-2 99.87%
    L-Lysine-13C6,15N2 (hydrochloride) is the 13C- and 15N-labeled L-Lysine hydrochloride. L-lysine hydrochloride is an essential amino acid for humans with various benefits including treating herpes, increasing calcium absorption, reducing diabetes-related illnesses and improving gut health.
    L-Lysine-13C6,15N2 hydrochloride
  • HY-W040055
    Neopterin 2009-64-5 99.90%
    Neopterin is an immune system activator metabolized by GTP and can be produced by activated macrophages. Neopterin has the potential to resist vascular inflammation and atherosclerosis. Neopterin inhibits the phosphorylation of NF-κB and promotes the expression of PPAR-γ, thereby suppressing the inflammatory response of vascular endothelial cells, reducing the formation of macrophage foam cells, and regulating the migration and proliferation of vascular smooth muscle cells. Neopterin can be used in research fields such as cardiovascular diseases (such as atherosclerosis), inflammation-related diseases and tumor immunomonitoring.
    Neopterin
  • HY-N0852
    Benzoylpaeoniflorin 38642-49-8 99.35%
    Benzoylpaeoniflorin, a natural product from Chinese paeony root, has the potential for coronary heart disease by decreasing apoptosis.
    Benzoylpaeoniflorin
Cat. No. Product Name / Synonyms Application Reactivity